370 related articles for article (PubMed ID: 29043014)
1. An open-label study to evaluate the long-term safety and efficacy of lanadelumab for prevention of attacks in hereditary angioedema: design of the HELP study extension.
Riedl MA; Bernstein JA; Craig T; Banerji A; Magerl M; Cicardi M; Longhurst HJ; Shennak MM; Yang WH; Schranz J; Baptista J; Busse PJ
Clin Transl Allergy; 2017; 7():36. PubMed ID: 29043014
[TBL] [Abstract][Full Text] [Related]
2. Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.
Banerji A; Riedl MA; Bernstein JA; Cicardi M; Longhurst HJ; Zuraw BL; Busse PJ; Anderson J; Magerl M; Martinez-Saguer I; Davis-Lorton M; Zanichelli A; Li HH; Craig T; Jacobs J; Johnston DT; Shapiro R; Yang WH; Lumry WR; Manning ME; Schwartz LB; Shennak M; Soteres D; Zaragoza-Urdaz RH; Gierer S; Smith AM; Tachdjian R; Wedner HJ; Hebert J; Rehman SM; Staubach P; Schranz J; Baptista J; Nothaft W; Maurer M;
JAMA; 2018 Nov; 320(20):2108-2121. PubMed ID: 30480729
[TBL] [Abstract][Full Text] [Related]
3. Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies.
Busse PJ; Farkas H; Banerji A; Lumry WR; Longhurst HJ; Sexton DJ; Riedl MA
BioDrugs; 2019 Feb; 33(1):33-43. PubMed ID: 30539362
[TBL] [Abstract][Full Text] [Related]
4. Interventions for the long-term prevention of hereditary angioedema attacks.
Beard N; Frese M; Smertina E; Mere P; Katelaris C; Mills K
Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013403. PubMed ID: 36326435
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
Banerji A; Busse P; Shennak M; Lumry W; Davis-Lorton M; Wedner HJ; Jacobs J; Baker J; Bernstein JA; Lockey R; Li HH; Craig T; Cicardi M; Riedl M; Al-Ghazawi A; Soo C; Iarrobino R; Sexton DJ; TenHoor C; Kenniston JA; Faucette R; Still JG; Kushner H; Mensah R; Stevens C; Biedenkapp JC; Chyung Y; Adelman B
N Engl J Med; 2017 Feb; 376(8):717-728. PubMed ID: 28225674
[TBL] [Abstract][Full Text] [Related]
6. Lanadelumab for the prevention of attacks in hereditary angioedema.
Valerieva A; Senter R; Wu MA; Zanichelli A; Cicardi M
Expert Rev Clin Immunol; 2019 Dec; 15(12):1239-1248. PubMed ID: 31721602
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of lanadelumab in Japanese patients with hereditary angioedema: A phase 3 multicenter, open-label study.
Hide M; Ohsawa I; Nurse C; Yu M;
J Dermatol; 2023 Nov; 50(11):1381-1391. PubMed ID: 37574953
[TBL] [Abstract][Full Text] [Related]
8. Lanadelumab to treat hereditary angioedema.
Wedi B
Drugs Today (Barc); 2019 Jul; 55(7):439-448. PubMed ID: 31347612
[TBL] [Abstract][Full Text] [Related]
9. Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study.
Banerji A; Bernstein JA; Johnston DT; Lumry WR; Magerl M; Maurer M; Martinez-Saguer I; Zanichelli A; Hao J; Inhaber N; Yu M; Riedl MA;
Allergy; 2022 Mar; 77(3):979-990. PubMed ID: 34287942
[TBL] [Abstract][Full Text] [Related]
10. Lanadelumab: A Review in Hereditary Angioedema.
Syed YY
Drugs; 2019 Nov; 79(16):1777-1784. PubMed ID: 31560114
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hereditary angioedema-single or multiple pathways to the rescue.
Valerieva A; Longhurst HJ
Front Allergy; 2022; 3():952233. PubMed ID: 36172291
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, Pharmacodynamics, and Exposure-Response of Lanadelumab for Hereditary Angioedema.
Wang Y; Marier JF; Kassir N; Chang C; Martin P
Clin Transl Sci; 2020 Nov; 13(6):1208-1216. PubMed ID: 32407574
[TBL] [Abstract][Full Text] [Related]
13. A review of kallikrein inhibitor lanadelumab in hereditary angioedema.
Hwang G; Johri A; Ng S; Craig T
Immunotherapy; 2019 Aug; 11(11):937-944. PubMed ID: 31234673
[TBL] [Abstract][Full Text] [Related]
14. Long-term lanadelumab treatment improves health-related quality of life in patients with hereditary angioedema.
Lumry WR; Maurer M; Weller K; Riedl MA; Watt M; Yu M; Devercelli G; Meunier J; Banerji A;
Ann Allergy Asthma Immunol; 2023 Jul; 131(1):101-108.e3. PubMed ID: 37028510
[TBL] [Abstract][Full Text] [Related]
15. Lanadelumab for the treatment of hereditary angioedema.
Wu MA
Expert Opin Biol Ther; 2019 Dec; 19(12):1233-1245. PubMed ID: 31657963
[No Abstract] [Full Text] [Related]
16. Safety Aspects and Rational Use of Lanadelumab Injections in the Treatment of Hereditary Angioedema (HAE): Clinical Insights.
Petkova E; Yordanova V; Staevska M; Valerieva A
Drug Healthc Patient Saf; 2022; 14():195-210. PubMed ID: 36578774
[TBL] [Abstract][Full Text] [Related]
17. Indirect Comparison of Lanadelumab and Intravenous C1-INH Using Data from the HELP and CHANGE Studies: Bayesian and Frequentist Analyses.
Mendivil J; Malmenäs M; Haeussler K; Hunger M; Jain G; Devercelli G
Drugs R D; 2021 Mar; 21(1):113-121. PubMed ID: 33646565
[TBL] [Abstract][Full Text] [Related]
18. Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
Riedl MA; Maurer M; Bernstein JA; Banerji A; Longhurst HJ; Li HH; Lu P; Hao J; Juethner S; Lumry WR;
Allergy; 2020 Nov; 75(11):2879-2887. PubMed ID: 32452549
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic monoclonal antibodies with a focus on hereditary angioedema.
Zuraw BL; Maurer M; Sexton DJ; Cicardi M
Allergol Int; 2023 Jan; 72(1):54-62. PubMed ID: 35787344
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Craig TJ; Reshef A; Li HH; Jacobs JS; Bernstein JA; Farkas H; Yang WH; Stroes ESG; Ohsawa I; Tachdjian R; Manning ME; Lumry WR; Saguer IM; Aygören-Pürsün E; Ritchie B; Sussman GL; Anderson J; Kawahata K; Suzuki Y; Staubach P; Treudler R; Feuersenger H; Glassman F; Jacobs I; Magerl M
Lancet; 2023 Apr; 401(10382):1079-1090. PubMed ID: 36868261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
